

November 11, 2021

## A Noteworthy Performance

#### **Lubricant Sales Attain Record High**

CONOIL recorded an impressive topline performance in 9M:2020, as revenue surged by 14.62%YoY to NGN100.9bn in the period. The stellar performance reflected the significant growth in product sales from all business segments as both white product (PMS, ATK, AGO, HHK) and lubricant grew by 14.03% and 23.63%, respectively. Highlighting the third quarter, revenue also expanded when compared to the corresponding period last year (+8.80%YoY), albeit suffering a contraction of 3.49%QoQ. We take note of the rise in economic activities which has supported the demand for petroleum product, thus translating to an increase in sales volume for the company. White product sales amounted to NGN94.27bn in the first nine months posting a growth of 14.03%YoY. Similarly, revenue from lubricant sales also gained traction, now at a record high of NGN6.71bn in 9M:2021 (23.63%YoY) - a CAGR of 24.03% between 2017 and 2021. The company continues to take advantage of its expansive retail presence, with over 300+ filling stations sited across the nation. We however worry about the LPG (cooking gas) business which remains dormant till date. Considering the recent surge in gas prices wherein industry players have raked in topline gains, CONOIL's inactivity in that space leaves "low hanging value on the table". However, based on improved volumes arising from increased demand compared to last year, we project a revenue growth of 14.73%YoY to pitch at NGN134.77bn for the financial year.


#### **CONOIL Financial Obligations Tapers**

The substantial increase in oil prices had its dire consequences for petroleum marketers as production cost for all business segment climbed higher in the nine-month period. Cost derived from both fuel and lubricant sales increased significantly by 14.03% to NGN94.27bn and 23.63% to NGN6.71bn, respectively. Overall direct cost outpaced revenue, increasing by 15.94%YoY to NGN92.94bn (vs. NGN80.16bn in 9M:2020) in 9M:2021. This raised the cost-to-sales ratio of the business to 92.04% from 90.98% recorded in 9M:2020. Notwithstanding, operating efficiency moved upward during the period to 5.27% (vs. 6.47% in 9M:2020), resulting from a decline in administrative expense by 9.13%YoY (the final ligation fee paid in 2020FY moderated administrative expense Year-to-Date). CONOIL's continues to benefit from the lower effective interest rate renegotiated at the start of the year (14% from 15.00% obtained in 2020FY.) with debt cost declining to NGN0.48bn from NGN0.83bn (-41.96%YoY) paid in 9M:2020. Total debt remains one of the lowest in the industry at NGN7.31bn compared to downstream industry average of NGN8.70bn. Profit before tax in turn improved by 43.54%YoY to NGN2.34bn. Tax on profit amounted to NGN0.75bn with effective tax rate remaining the same at 32%. Net profit also increased to 43.54%YoY to NGN1.59bn with net margin improving by 32bp to 1.58% (vs. 1.26% seen in 9M:2020). The resulted to shareholders reaping more value from their investment as ROE improved to 7.55% from 5.40% seen in 9M:2020. On this note, we still maintain our full year projection for earnings to reach NGN2.24bn, up by 55.72%YoY which would be driven by improved sales turnover as well as lower debt cost.

#### Recommendation

Based on the projected earnings for 2021FY, EPS estimated at NGN3.23 and target P/E of 8.20x. This implies a target price of NGN26.50 thus presenting an upside of 22.12%. Hence, we recommend a **BUY**.

Company	CONOIL
Valuation	
Trailing EPS	2.77
BVPS	30.43
P/E	7.83
P/BV	0.71
Target PE	8.20x
Dec-2021 Exp. EPS	3.23
Dec 2021 Target price	NGN26.50
Current Price	NGN21.70
Up/Downside Potential	22.12%
Ratings	BUY
Key metrics	
ROE	9.11%
ROA	3.94%
Net margin	1.58%
Asset Turnover	2.07x
Leverage	2.31x
Share Price Data	
Year High	25.50
Year Low	17.00
YTD return	4.08%
Beta	1.18
Adjusted Beta	1.12
Shares outstanding	0.69bn
Market cap [NGN]	15.06bn
Financial year end	December
Most Recent Period	
(MRP)	9M:2021





November 11, 2021

## **Chart 1: Sensitivity Analysis**

Sensitivity Analysis of H1:2021 Target Price to key model inputs								25.37
				EPS			Max	27.65
		3.13	3.18	3.23	3.28	3.33	_	
	8.10x	25.37	25.77	26.18	26.58	26.99	-	
Toward DE	8.15x	25.52	25.93	26.34	26.75	27.15		
Target PE	8.20x	25.68	26.09	26.50	26.91	27.32		
	8.25x	25.84	26.25	26.66	27.07	27.49		
	8.30x	25.99	26.41	26.82	27.24	27.65	_	

Financial Highlights and Forecasts (NGN billion)							
Profit & Loss Account	9M:2020	9M:2021	2021F	2022F	2023F	2024F	2025F
Revenue	88.10	100.98	134.77	147.73	150.68	153.69	156.77
Cost of sales	80.16	92.94	123.53	134.19	134.70	137.39	140.14
Gross Profit	7.94	8.04	11.25	13.54	15.98	16.30	16.63
OPEX	5.70	5.32	7.64	8.79	8.91	8.97	9.20
Other Income	0.21	0.10	0.20	0.18	0.20	0.20	0.21
Operating Profit	2.25	2.72	3.80	4.92	7.27	7.53	7.64
Finance Cost	0.83	0.48	0.59	0.91	1.21	1.21	0.61
PBT	1.63	2.34	3.29	4.11	6.06	6.33	7.03
PAT	1.11	1.59	2.24	2.81	4.16	4.34	4.81

Balance Sheet	2020FY	9M:2021	2021F	2022F	2023F	2024F	2025F
Property, Plant and Equipment	2.30	1.49	1.51	1.94	1.86	1.77	2.26
Total Debt	0.19	6.03	5.03	2.03	6.03	3.03	1.03
Total Assets	48.86	48.83	59.37	71.40	74.83	75.28	78.10
Total Equity	19.52	21.11	20.37	21.79	24.56	27.52	30.94
Total Current Liabilities	28.38	26.75	38.03	48.63	49.29	46.78	46.18
Non-Current Liabilities	0.96	0.96	0.97	0.97	0.97	0.98	0.98
Total Liabilities	29.34	27.71	39.00	49.60	50.27	47.76	47.16

Financial Ratios	9M:2020	9M:2021	2021F	2022F	2023F	2024F	2025F
Gross Margin	9.02%	7.96%	8.35%	9.16%	10.61%	10.61%	10.61%
Operating Margin	2.55%	2.69%	2.82%	3.33%	4.82%	4.90%	4.87%
Net Margin	1.26%	1.58%	1.66%	1.90%	2.76%	2.82%	3.07%
Return on Asset	2.95%	3.94%	3.78%	3.93%	5.56%	5.77%	6.16%
Return on Equity	7.38%	9.11%	11.01%	12.88%	16.93%	15.77%	15.54%
Return on Invested Capital	0.00x	0.00x	0.11x	0.14x	0.18x	0.17x	0.17x
Earnings Per Share	1.60x	2.30x	3.23x	4.05x	5.99x	6.26x	6.93x
Asset Turnover	1.80x	2.07x	2.27x	2.07x	2.01x	2.04x	2.01x
Financial Leverage	2.50x	2.31x	2.91x	3.28x	3.05x	2.74x	2.52x
Debt to Asset Ratio	0.00x	0.12x	0.08x	0.03x	0.08x	0.04x	0.01x
Debt to EBIT Ratio	0.08x	2.22x	1.32x	0.41x	0.83x	0.40x	0.13x
Current Ratio	1.55x	1.67x	1.45x	1.38x	1.43x	1.52x	1.59x
Quick Ratio	1.28x	1.43x	1.27x	1.18x	1.28x	1.32x	1.42x



November 11, 2021

## **Contact Information**

**Brokerage and Retail Services** 

topeoludimu@meristemng.com (+234 905 569 0627) olatunjifaniyi@meristemng.com (+234 803 446 3118) isaaconaolapo@meristemng.com (+234 803 234 8275)

contact@meristemng.com

**Investment Banking/Corporate Finance** 

rasakisalawu@meristemng.com (+234 806 022 9889) (+234 808 536 5766) seunlijofi@meristemng.com

Wealth Management

funmilolaadekola-daramola@meristemng.com (+234 805 498 4522)

crmwealth@meristemng.com Tel: +234 01 738 9948

Registrars

muboolasoko@meristemregistrars.com (+234 803 324 7996) martinaosague@meristemregistrars.com (+234 802 303 1783)

www.meristemregistrars.com

trustees@meristemng.com

Tel: +23401-280 9250

**Trust Services** 

damilolahassan@meristemng.com (+234 803 613 9123)

**Group Business Development** 

saheedbashir@mersitemng.com (+234 802 454 6575) ifeomaogalue@meristemng.com (+234 802 3942967)

info@meristemng.com

Client Services

adefemitaiwo@meristemng.com (+234 803 694 3034) blessingogwuche@meristemng.com (+234 706 896 5173)

car@meristemng.com

Investment Research

ahmedjinad@meristemng.com (+234 809 183 9487)

research@meristemng.com

www.meristemwealth.com **Corporate websites:** www.meristemng.com www.meristemregistrars.com

Meristem Research can also be accessed on the following platforms:

Meristem Research portal: research.meristemng.com

Bloomberg: MERI <GO>

Capital IQ: www.capitaliq.com Reuters: www.thomsonreuters.com FactSet: www.factset.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG

NGX: CONOIL I Bloomberg: CONOIL:NL I Reuters: CONOIL.LG



November 11, 2021

### **Analyst's Certification and Disclaimer**

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

**Analysts' Compensation:** The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

### **Investment Ratings**

#### **Fair Value Estimate**

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

#### **Target Price Estimate**

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

#### **Ratings Specification**

BUY: Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.

**SELL**: Target Price of the stock is more than **10 percent** below the current market price.



November 11, 2021

#### **Definitions**

**Price Targets:** Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

**Asset allocation:** The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

### **Movements in Price Target**

Company Name: Conoil Plc

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
11-Nov-2021	21.70	26.50	26.50	BUY	BUY
16-Sep-2021	22.35	24.24	26.50	HOLD	BUY

### **Company disclosures**

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

Company	Disclosure
Company	Disclosure
Conoil Plc	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



November 11, 2021

#### **Conflict of Interest**

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

### **Important Disclosure**

**For U.S. persons only:** This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Mersitem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

### Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2021 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited.